Loading clinical trials...
Loading clinical trials...
Retrospective Exploratory Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients
Determine the levels of Donor-derived (dd)cell-free DNA(cfDNA )in liver transplant recipients with normal liver function tests (LFTs) indicating stable immunosuppression status (IS). Based on this range use the dd-cfDNA levels to determine over or under IS in liver transplant patients to make changes to their IS medication regimen.
dd-cfDNA is a non-invasive method to measure graft function stability in liver transplant patients. Liver biopsy is the standard to determine liver rejection and graft function, but no tests exist currently to be able to help guide the IS regimen in these patients. LFTs are not as specific to determine graft function hence testing dd-cfDNA levels can help guide the Immunosuppression (IS )medications dosing and help identify rejection early.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Methodist Dallas Medical Center
Dallas, Texas, United States
Start Date
July 1, 2021
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2024
Last Updated
March 28, 2024
300
ESTIMATED participants
donor-derived cell free DNA in liver
BEHAVIORAL
Lead Sponsor
Methodist Health System
NCT05866796
NCT04756063
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04789213